CliffBio
small molecule

JANUVIA

SITAGLIPTIN PHOSPHATE

Loss of exclusivityMay 2027latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME LLC

Drug detail

Brand nameJANUVIA
Active ingredientSITAGLIPTIN PHOSPHATE
StrengthEQ 50MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2006
Marketing statusRX

Listed patents

PatentExpiresType
7326708*PEDMay 2027—
7326708November 2026substance, product

More from MERCK SHARP AND DOHME LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JANUVIA patent cliff — loss of exclusivity May 2027 | CliffBio